Status: Recruiting
Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study
This is a prospective and single arm clinical study. The goal of this clinical trial is to observe and evaluate the efficacy and safety of Daratumumab/daratumumab and hyaluronidase-fihj in combination with pomalidomide and dexamethasone in the treatment of patients with newly diagnosed AL amyloidosis.
Participants needed: 20
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Yongyong MAUpdated: Jun 12, 2024Locations: 1
Eligibility criteria
Age: 18-80 years old, diagnosed with primary amyloidosis of AL tissue; [+7]
Non AL amyloidosis; [+16]